CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 94 filers reported holding CONCERT PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,645,688 | +103.7% | 281,796 | +133.7% | 0.00% | – |
| Q3 2022 | $808,000 | +88.3% | 120,598 | +18.4% | 0.00% | – |
| Q2 2022 | $429,000 | +68.2% | 101,898 | +34.4% | 0.00% | – |
| Q1 2022 | $255,000 | +14.3% | 75,798 | +7.2% | 0.00% | – |
| Q4 2021 | $223,000 | -3.5% | 70,740 | 0.0% | 0.00% | – |
| Q3 2021 | $231,000 | -27.1% | 70,740 | -5.7% | 0.00% | – |
| Q2 2021 | $317,000 | -86.5% | 75,040 | -84.0% | 0.00% | – |
| Q1 2021 | $2,343,000 | -62.4% | 469,455 | -4.7% | 0.00% | – |
| Q4 2020 | $6,226,000 | +28.2% | 492,588 | -0.4% | 0.00% | – |
| Q3 2020 | $4,856,000 | +0.7% | 494,454 | +2.0% | 0.00% | – |
| Q2 2020 | $4,823,000 | +16.3% | 484,709 | +3.3% | 0.00% | – |
| Q1 2020 | $4,146,000 | +10.1% | 469,020 | +14.9% | 0.00% | – |
| Q4 2019 | $3,766,000 | +58.6% | 408,256 | +1.1% | 0.00% | – |
| Q3 2019 | $2,374,000 | -47.6% | 403,725 | +7.0% | 0.00% | – |
| Q2 2019 | $4,528,000 | -3.6% | 377,332 | -3.1% | 0.00% | – |
| Q1 2019 | $4,699,000 | -15.8% | 389,291 | -12.4% | 0.00% | -100.0% |
| Q4 2018 | $5,579,000 | -15.6% | 444,510 | -0.3% | 0.00% | 0.0% |
| Q3 2018 | $6,612,000 | -5.4% | 445,793 | +7.3% | 0.00% | 0.0% |
| Q2 2018 | $6,990,000 | -20.1% | 415,318 | +8.7% | 0.00% | 0.0% |
| Q1 2018 | $8,744,000 | +15.8% | 381,912 | +30.9% | 0.00% | 0.0% |
| Q4 2017 | $7,548,000 | +62.6% | 291,652 | -7.4% | 0.00% | – |
| Q3 2017 | $4,641,000 | +10.9% | 314,842 | +4.9% | 0.00% | – |
| Q2 2017 | $4,186,000 | -10.4% | 300,093 | +9.5% | 0.00% | – |
| Q1 2017 | $4,673,000 | +30.0% | 274,069 | -21.6% | 0.00% | – |
| Q4 2016 | $3,594,000 | +5.5% | 349,505 | +3.8% | 0.00% | – |
| Q3 2016 | $3,406,000 | -8.1% | 336,815 | +2.1% | 0.00% | – |
| Q2 2016 | $3,708,000 | -18.2% | 329,769 | -0.6% | 0.00% | – |
| Q1 2016 | $4,531,000 | +6.4% | 331,605 | +47.7% | 0.00% | – |
| Q4 2015 | $4,260,000 | +17.8% | 224,559 | +16.5% | 0.00% | – |
| Q3 2015 | $3,617,000 | +96.7% | 192,814 | +55.9% | 0.00% | – |
| Q2 2015 | $1,839,000 | +988.2% | 123,706 | +1004.5% | 0.00% | – |
| Q1 2015 | $169,000 | -71.4% | 11,200 | -74.5% | 0.00% | – |
| Q1 2014 | $590,000 | – | 43,859 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 2,610 | $620,000,000 | 6.47% |
| Parkman Healthcare Partners LLC | 1,124,072 | $4,732,000 | 1.74% |
| Kynam Capital Management, LP | 1,000,000 | $4,210,000 | 1.08% |
| EAM Investors, LLC | 850,647 | $3,581,000 | 0.87% |
| BVF INC/IL | 3,629,000 | $15,278,000 | 0.74% |
| EAM Global Investors LLC | 388,730 | $1,637,000 | 0.40% |
| RA Capital Management | 3,307,203 | $13,923,000 | 0.37% |
| Nantahala Capital Management | 1,659,840 | $6,988,000 | 0.35% |
| AWM Investment Company, Inc. | 504,661 | $2,125,000 | 0.34% |
| INGALLS & SNYDER LLC | 1,411,153 | $5,941,000 | 0.31% |